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Abstract
Nonislet cell tumour-induced hypoglycaemia is an uncommon, but serious complication of malignancy. The 
aetiopathogenesis is largely as a result of tumoral overproduction of incompletely processed insulin-like growth 
factor-II. We describe the case of a 30-year-old black male patient who presented with recurrent hypoglycaemic 
episodes in the absence of diabetes or any medications known to cause hypoglycaemia. Extensive investigations 
revealed that the hypoglycaemia was the result of an advanced hepatocellular carcinoma. 
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Introduction
Hypoglycaemia is a common medical emergency. It 
occurs mostly as a consequence of therapy with insulin 
and/or oral sulphonylureas in the setting of diabetes 
mellitus. There are numerous other causes that include 
neoplastic diseases. The most common cause of this 
type of hypoglycaemia is tumoral overproduction of 
insulin-like growth factor-II (IGF-II).
Case description
A 30-year old Malawian male presented to Chris Hani 
Baragwanath Academic Hospital in a comatose state. 
There was no history of diabetes mellitus, drugs or toxin 
exposure. In addition, there was no history of trauma 
or seizures.
Neurologically, there was no meningism or focal signs. 
His blood pressure was 111/79 mmHg, with a pulse rate 
of 87 beats per minute and a temperature of 36.8oC. The 
rest of his examination was unremarkable except for a 
15cm (vertical span) firm and irregular hepatomegaly. 
Initial blood investigations confirmed hypoglycaemia 
with a glucose level of 2.1 mmol/l. C-peptide and 
insulin levels taken at the time of the hypoglycaemic 
event were appropriately suppressed (Table I). The 
cortisol level of 331 nmol/l was inappropriately low for 
the degree of hypoglycaemia. However, a synacthen 
stimulation test excluded any evidence of adrenal 
insufficiency. Liver function tests showed an enzyme 
pattern that was consistent with space-occupying 
lesions. The α-fetoprotein was markedly elevated (Table 
I). Hepatitis B studies indicated a chronic carrier state.
Table I: Relevant blood results during a hypoglycaemic episode
Blood test Patient’s value Normal values
Glucose 2.1 mmol/l 3.6-5.5 mmol/l (fasting)
Insulin < 2.0 μU/l 0.0-29.1 μU/l (fasting)
C-peptide 0.2 ng/l 0.9-7.1 ng/l (fasting)
α-fetoprotein 10 728 μg/l 0-7 μg/l
An abdominal sonar revealed multiple hypodense 
lesions throughout the liver. Computed tomography of 
the abdomen confirmed numerous lesions in both the 
right and left lobes of the liver, highly suggestive of a 
hepatocellular carcinoma (HCC) (Figure 1). The liver 
biopsy confirmed the diagnosis of HCC (Figures 2-4).
The patient continued to experience ongoing 
hypoglycaemic episodes, despite a continuous 
intravenous infusion of 5% dextrose water. A serum 
sample, taken during a hypoglycaemic episode, was 
analysed at the Royal Surrey County Hospital NHS 
Foundation Trust in Surrey, UK, for the measurement 
of insulin-like growth factors I and II (IGF-I and IGF-II), 
by radioimmunoassay technique. The results demon-
strated a virtually suppressed IGF-I level with an 
elevated IGF-II:IGF-I ratio (Table II). These findings were 
in keeping with the diagnosis of nonislet cell tumour-
induced hypoglycaemia.
The patient was managed with a continuous dextrose 
(10%) infusion, together with a complex carbohydrate 
diet, but he continued to experience ongoing hypo-
glycaemic events. Subsequently, oral prednisone was 
initiated at a dose of 40 mg daily, which dramatically 
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improved the ongoing hypoglycaemic episodes. 
Palliative care was implemented in view of the 
advanced stage of the patient’s malignancy.
Discussion
Nonislet cell tumour-induced hypoglycaemia is an 
uncommon, but serious complication of malignancy. 
Usually, it is caused by a variety of benign and 
malignant tumours, including HCC. The hypoglycaemia 
is mediated by tumoral overproduction of incompletely 
processed IGF-II.1 Rarely, it may be mediated by 
other factors, including insulin receptor antibodies, 
metastatic destruction of the liver and various other 
hypoglycaemic cytokines. The exact incidence and 
prevalence of nonislet cell tumour-induced hypo-
glycaemia is not known, but it is estimated to be four 
times less common than insulinoma.2 
The IGF-II gene is an imprinted gene, with parental 
allele specific expression. It is maternally imprinted 
and encoded on chromosome 11p15, together with 
two tumour-suppressor genes, H19 and p57. As a 
consequence of imprinting loss or mutations in either 
of these two genes, IGF-II is overexpressed and hence 
overproduced.3
Under normal circumstances, the precursor molecule, 
prepro-IGF-II, is converted to pro-IGF-II, which in turn is 
converted to mature IGF-II in the presence of various 
enzymes, the majority of which are bound to IGF-
binding proteins (IGFBP). Mature IGF-II is mostly bound 
to IGFBP3, and to a lesser extent IGFBP5, as a 150-kDa 
ternary complex, together with an acid-labile subunit. 
Because of its high molecular mass, this complex is 
unable to pass through the capillary membrane and 
remains confined to the intravascular space, and 
hence is less bioactive at a cellular level. Most of the 
biological actions of IGF-II are mediated via the IGF-I 
Figure 1: Computed tomography imaging of the liver, showing 
multiple lesions
Figure 2: Haematoxylin and eosin stain, demonstrating nests of 
atypical hepatocytes (x 40)
Figure 3: A focal Hep Par 1 stain, confirming that the tumour is of 
hepatic origin (x 400)
Figure 4: A diffusively positive MOC-31 stain, suggesting a poorly 
differentiated variant of hepatocellular carcinoma (x 400)
Table II: Insulin-like growth factor levels
Blood test Patient’s values Normal values
IGF-I < 3.2 nmol/l 13-50 nmol/l
IGF-II 99.8 nmol/l 55-150 nmol/l
IGF-II:IGF-I molar ratio 28.3:1 < 10:1
IGF-I: insulin-like growth factors I, IGF-II: insulin-like growth factors II
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receptor and insulin receptor, which effect a strong 
mitogenic and antiapoptotic activity.4 Seventy per 
cent of IGF-II exists in the mature form and 30% as 
incompletely processed pro-IGF-II in normal human 
serum.5 
In the setting of tumours, the major form of circulating 
IGF-II is a high molecular weight IGF-II, designated 
“big” IGF-II, the generation of which is unclear, but has 
been proposed to be the result of abnormal processing 
of pro-IGF-II.6 “Big” IGF-II has a greater bioavailability 
than mature IGF-II as it mostly circulates as smaller 
(150-kDa) binary complexes or in a “free”, unbound 
form and is thus biologically more active at a cellular 
level. Upon binding to the insulin and IGF-1 receptors, 
various secondary changes in the circulating levels 
of insulin, growth hormone, IGF-I and IGFBP result, 
mediating an insulin-like hypoglycaemic activity of 
“big” IGF-II.7
Increased levels of “big” IGF-II, as well as an elevated 
ratio of total IGF-II:IGF-I are useful markers in diagnosing 
nonislet cell tumour-induced hypoglycaemia. The 
normal molar ratio of IGF-II:IGF-I in plasma is usually 
3:1. A ratio of greater than 10:1 is considered to be 
pathognomonic of nonislet cell tumour-induced 
hypoglycaemia.2 In response to the hypoglycaemia, 
and via activation of the insulin receptor by IGF-
II, endogenous insulin and C-peptide levels are 
suppressed.
Conventional radiological imaging, using computed 
tomography or magnetic resonance imaging, readily 
detects tumours that cause nonislet cell tumour-
induced hypoglycaemia as they are usually large on 
presentation.
Therapeutic strategies include complete removal of 
the tumour or reduction of the tumour mass, which 
alleviates the metabolic alterations caused by nonislet 
cell tumour-induced hypoglycaemia.1,7 If surgery is not 
feasible, and curative resection not possible, various 
approaches to the treatment of nonislet cell tumour-
induced hypoglycaemia have been tried. These 
include diazoxide, glucocorticosteroids, somatostatin 
analogues and growth hormone therapy. Interestingly, 
diazoxide-chlorothiazide treatment often alleviates 
nonislet cell tumour-induced hypoglycaemia, though 
less predictably than with insulinomas.
Usually, large doses of glucocorticoids are the most 
effective therapy in terms of long-term relief from 
hypoglycaemia through the stimulation of gluco-
neogenesis and suppression of the production of “big” 
IGF-II.8-10 This beneficial effect is dose-dependent and is 
reversed when therapy is withdrawn. To date, no clear 
benefit has been demonstrated with either human 
growth hormone or somatostatin analogues alone. 
However, the combined usage of growth hormone 
and steroids may alleviate symptoms.8,11
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